January 10, 2020Open Access

Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States

Key Points

Key points are not available for this paper at this time.

Abstract

Therapeutic inertia is common in routine clinical practice and makes a substantial contribution to the burden associated with type 2 diabetes in the USA. Initiatives and interventions aimed at preventing therapeutic inertia are needed to improve clinical outcomes and avoid excess costs.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Sarah Ali

Tam Dang‐Tan

William J. Valentine

Journals

Advances in Therapy

Actions

Institutions

Novo Nordisk (Denmark)

Novo Nordisk (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider